Business
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
Updated interim results with an additional ~13 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-tolerated Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.1 in the first 23 patients in Cohort 2 and both patients in Cohort 1Objective response in 39% of patients in Cohort 2 regardless of SSTR2 expression profile, including one Cohort 2 patient who experienced an initial objective response pending confirmation sin
![Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium](https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9)
About this update from Perspective Therapeutics, Inc.
[{"type":"image","alt":"Perspective Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Perspective Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QSFbVndZiJCez3FgWA5yTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9","width":300,"height":63}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Updated interim results with an additional ~13 weeks of follow-up since the prior update","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"[212Pb]VMT-α-NET continues to be well-tolerated ","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.1 in the first 23 patients in Cohort 2 and both patients in Cohort 1","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"Objective response in 39% of patients in Cohort 2 regardless of SSTR2 expression profile, including one Cohort 2 patient who experienced an initial objective response pending confirmation since the prior update, and 8 previously reported confirmed responders","length":258,"tagName":"p"}]},{"val":[{"type":"text","content":"Cohort 3 (6.0 mCi) dose limiting toxicities (DLT) assessment completed as planned; cleared to treat more patients with one additional patient already treated ","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Initial efficacy data pending for another 23 patients in Cohort 2 and 8 patients in Cohort 3; submissions to more medical conferences in 2026 are planned, as well as regulatory engagement","length":192,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":915,"olType":false},{"type":"text","content":"SEATTLE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin r...